Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


NAD reviews Natrol’s BioSil

This article was originally published in The Tan Sheet

Executive Summary

Natrol provided "reasonable support" for claims it made for its liquid dietary supplement BioSil, which is indicated to promote the health of skin, hair, nails and bones in women, but the firm should modify or discontinue certain claims, according to an Oct. 21 National Advertising Division decision. NAD said Natrol, a subsidiary of India-based Plethico Pharmaceuticals, substantiated some claims with three double-blind, placebo-controlled clinical trials. However, NAD recommended the firm discontinue the claims that BioSil "reduced fine lines and wrinkles by 19 percent" and that the product is "clinically proven to give a more youthful look" in 20 weeks. Natrol said while it disagrees with NAD that some of its claims are overly broad, it will comply with the recommendations





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts